By Christopher Capot. WRAL Tech Wire News
RESEARCH TRIANGLE PARK – ProKidney LLC, a Winston-Salem-based clinical-stage biotechnology company founded in 2015 and targeting chronic kidney disease (CKD) with a proprietary cell therapy, plans to create up to 330 jobs and establish a new manufacturing facility in Greensboro by 2027.
On Tuesday, the NC Department of Commerce and Gov. Roy Cooper announced that ProKidney will invest up to $485 million into the project, of which $25.5 million will be invested to establish a 210,000-square-foot facility on about 22 acres in Greensboro. The facility will support the future commercial manufacturing of REACT (REnal Autologous Cell Therapy), the company’s lead product candidate targeting CKD.
“Innovative life science companies like ProKidney understand that North Carolina offers the key ingredients for business success,” said Cooper, in a news release. “Our leadership in this important industry sector is recognized around the world, thanks to the specialized workforce training and education systems that support North Carolina’s biotech companies.”
/cloudfront-us-east-2.images.arcpublishing.com/reuters/4VIQAQSYVZJLPBBNKLEPW3Y55I.jpg "White House unveils billion biotech spending plan ahead of industry summit")